Sugar-enabledVAC Glycoengineered erythrocytes for better influenza vaccines
- Coordinator
- Universiteit Utrecht, Netherlands
- Runs
- 1 September 2022 to 29 February 2024
- Status
- Finished
- EU funding
- €150k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101081818
What the project is doing
In the project's own words, from its summary on CORDIS.
The objective of this ERC PoC project is to establish technical and commercial feasibility of our recently developed glycan-engineered red blood cells (RBCs) for antigenic characterization of circulating influenza A/H3N2 viruses. Due to the rapid evolution of influenza A/H3N2 viruses, antigenic characterization by the widely used hemagglutination inhibition (HI) assay is not possible anymore. Continuous antigenic characterization of influenza A viruses is, however, essential for the development of protective seasonal vaccines.
The ERC program “sugar-enable” has developed glycoengineered RBCs that make it possible again to antigenically characterize circulating A/H3N2 viruses by the standard HI assay, and it is expected that the cells will find application in hundreds of laboratories worldwide.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universiteit Utrecht | Utrecht | Netherlands | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI